3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
2
Myocardial Reperfusion Injury
2
Cardiotoxicity
2
Vomiting
1
Uveal Melanoma
1
Thrombosis
1
Retinal Diseases
1
Reperfusion Injury
1
Pain, Postoperative
1
Nausea
1
Melanoma
1
Macular Degeneration
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Choroid Diseases
1
Breast Neoplasms
1
Interventions
Ipilimumab
17
Nivolumab
15
incomplete Freund's adjuvant
8
Cyclophosphamide
7
CTLA-4 Antigen
7
pembrolizumab
6
Ranibizumab
6
sargramostim
5
Radiosurgery
5
Blood Specimen Collection
5
tebentafusp
4
Temozolomide
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
MART-1 Antigen
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
fludarabine
3
aflibercept
3
Thalidomide
3
Sunitinib
3
Specimen Handling
3
MAGEA3 protein, human
3
Interleukin-2
3
130-nm albumin-bound paclitaxel
3
relatlimab
2
olaparib
2
montanide ISA 51
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uveal Melanoma
×
salicylhydroxamic acid
×
Clear all
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled